Patents by Inventor Markus PRÖLS

Markus PRÖLS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY CHANGES TO THE RECTUM
    Publication number: 20260053818
    Abstract: Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
    Type: Application
    Filed: August 19, 2025
    Publication date: February 26, 2026
    Inventors: Rudolf WILHELM, Markus PRÖLS, Roland GREINWALD, Ralf MOHRBACHER
  • Pharmaceutical formulation for the treatment of inflammatory changes to the rectum
    Patent number: 12472191
    Abstract: Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
    Type: Grant
    Filed: July 12, 2023
    Date of Patent: November 18, 2025
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Markus Pröls, Roland Greinwald, Ralf Mohrbacher
  • Use of nor-ursodeoxycholic acid for reducing liver fat
    Patent number: 11850252
    Abstract: The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: December 26, 2023
    Assignee: DR. FALK PHARMA GMBH
    Inventors: Markus Pröls, Roland Greinwald, Michael Trauner, Peter Fickert
  • PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY CHANGES TO THE RECTUM
    Publication number: 20230364113
    Abstract: Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
    Type: Application
    Filed: July 12, 2023
    Publication date: November 16, 2023
    Inventors: Rudolph WILHELM, Markus PRÖLS, Roland GREINWALD, Ralf MOHRBACHER
  • Pharmaceutical formulation for the treatment of inflammatory changes to the rectum
    Patent number: 11738032
    Abstract: Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: August 29, 2023
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolph Wilhelm, Markus Pröls, Roland Greinwald, Ralf Mohrbacher
  • Optimized high-dose mesalazine-containing tablet
    Patent number: 11135159
    Abstract: The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 5, 2021
    Inventors: Rudolph Wilhelm, Markus Pröls, Roland Greinwald, Tanju Nacak
  • PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY CHANGES TO THE RECTUM
    Publication number: 20210100819
    Abstract: Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
    Type: Application
    Filed: November 10, 2020
    Publication date: April 8, 2021
    Inventors: Rudolph WILHELM, Markus PRÖLS, Roland GREINWALD, Ralf MOHRBACHER
  • Pharmaceutical formulation for the treatment of inflammatory changes to the rectum
    Patent number: 10905699
    Abstract: Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: February 2, 2021
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolph Wilhelm, Markus Pröls, Roland Greinwald, Ralf Mohrbacher
  • Use of Nor-Ursodeoxycholic Acid for Reducing Liver Fat
    Publication number: 20200246357
    Abstract: The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 6, 2020
    Inventors: Markus PRÖLS, Roland GREINWALD, Michael TRAUNER, Peter FICKERT
  • OPTIMISED HIGH-DOSE MESALAZINE-CONTAINING TABLET
    Publication number: 20180311155
    Abstract: The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 1, 2018
    Inventors: Rudolph WILHELM, Markus PRÖLS, Roland GREINWALD, Tanju NACAK
  • PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY CHANGES TO THE RECTUM
    Publication number: 20180200268
    Abstract: Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
    Type: Application
    Filed: June 28, 2016
    Publication date: July 19, 2018
    Inventors: Rudolph WILHELM, Markus PRÖLS, Roland GREINWALD, Ralf MOHRBACHER
  • Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
    Patent number: 10000526
    Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 19, 2018
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Markus Pröls, Erik Fischer, Heidi Waenerlund Poulsen
  • Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size
    Publication number: 20170057990
    Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 2, 2017
    Inventors: Rudolf WILHELM, Markus PRÖLS, Erik FISCHER, Heidi WAENERLUND POULSEN